{
  "docId": "019de073-8778-764b-accb-e5886cb9e840",
  "docSlug": "a27c0c380497fe380fc0ea99c606f1fe",
  "documentTitle": "Equillium | Results Presentation Deck | 32 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 32,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8778-764b-accb-e5886cb9e840/19",
  "deckHref": "/decks/019de073-8778-764b-accb-e5886cb9e840",
  "deckJsonHref": "/decks/019de073-8778-764b-accb-e5886cb9e840.json",
  "deckAnchorHref": "/decks/019de073-8778-764b-accb-e5886cb9e840#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.928,
        "x": 0.036,
        "y": 0.215
      },
      "kind": "list",
      "text": "Subcutaneous administration of itolizumab (0.4 - 2.4 mg/kg doses) was well tolerated\nReduced tolerability was observed at the 3.2 mg/kg dose with over 50% of patients discontinuing treatment after the first dose, 2-3 injections per dose were required\nConsistent with the mechanism of action of itolizumab, CD6 on the surface of T cells decreased significantly in a dose dependent fashion with maximal effect achieved at doses of 1.6 mg/kg or higher\nExploratory subgroup analysis of Type A SLE subjects with elevated baseline levels of proteinuria or albuminuria (without diagnosis of active lupus nephritis) showed a decline in proteinuria – up to 54% – at two months following two doses of itolizumab\nThe pharmacokinetic and pharmacodynamic analyses and the safety profile observed to date supports continued evaluation of subcutaneous itolizumab in SLE / LN (NCT04128579) and other chronic autoimmune diseases",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c01d0262-2881-4347-b665-3ad85e2beb96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.056,
        "w": 0.735,
        "x": 0.036,
        "y": 0.078
      },
      "kind": "title",
      "text": "Conclusions from Type A portion of EQUALISE Study",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60390c61-3b04-43db-ad35-87e888b0b821",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "9930205e-cb14-48bf-a859-7cc779b49c79",
      "evidence": "list/bullet: Subcutaneous administration of itolizumab (0.4 - 2.4 mg/kg doses) was well tolerated",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 31,
      "from": 10,
      "beatId": "74c9ceff-f718-432a-b48e-9f41e627272b",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Itolizumab's potential solution is presented, with efficacy and safety data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 31,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f935949f-a063-4f53-ae76-c20f25bdff22",
      "evidence": "The presentation implies the cost of inaction through the unmet medical need and limitations of current treatments.",
      "position": 0,
      "objective": "What is the cost of not treating Lupus Nephritis effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 10,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5a9857ab-edc2-421f-aac9-92c4e50656db",
      "evidence": "The presentation discusses itolizumab's mechanism of action and efficacy in treating Lupus Nephritis.",
      "position": 1,
      "objective": "What are the jobs to be done in treating Lupus Nephritis?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}